Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM)

NCT01000506 PHASE2 COMPLETED Results posted

The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	621
Start date	Sun Nov 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Asthma

Interventions

• Mepolizumab 750
• Mepolizumab 250
• Mepolizumab 75
• Placebo saline

Countries

France, Russia, Ukraine, Chile, United Kingdom, Germany, Poland, South Korea, Argentina, Canada, Romania, Australia, United States